Description

Novo Nordisk’s New Weapon In Obesity War: Higher Doses & No Needles!

Novo Nordisk stock has surged recently, driven by a combination of regulatory wins, strong early demand for new products, and growing investor confidence in its future obesity franchise. The most notable catalyst was the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) approving a new, higher 7.2 mg weekly dose of semaglutide (Wegovy) for adults with obesity—a major increase from the prior 2.4 mg cap. This follows on the heels of a strong U.S. launch for the oral version of Wegovy, with retail prescriptions totaling 3,071 in just its first week. Analysts at Berenberg project $1 billion in sales for the pill in 2026 alone, with upside to as much as $6 billion by 2027 depending on market execution. At the same time, competitive dynamics remain intense, particularly with Eli Lilly’s Zepbound gaining market share and its oral GLP-1 candidate, orforglipron, poised to enter the fray in 2026.